Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00046722 · ClinicalTrials.gov registry record · Phase 1
Marijuana for HIV-Related Peripheral Neuropathy
A Phase 1 study of HIV Infections and Peripheral Nervous System Diseases, sponsored by Center for Medicinal Cannabis Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00046722 is a Phase 1 study of HIV Infections and Peripheral Nervous System Diseases that has completed, run by Center for Medicinal Cannabis Research. The registered enrollment target is 50 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00046722, a Phase 1 study of HIV Infections and Peripheral Nervous System Diseases, has completed, sponsored by Center for Medicinal Cannabis Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate whether smoked marijuana reduces pain in people with HIV-related peripheral neuropathy.
Conditions Studied
Interventions
- DRUG Smoked Marijuana
Study Locations (1)
California
- University of California, San Francisco Community Consortium - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2003-01 |
| Est. Completion | 2005-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00046722
The ClinicalTrials.gov registry entry for NCT00046722 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (89% lower). The listed sponsor is Center for Medicinal Cannabis Research, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Smoked Marijuana is the first listed.
NCT00046722 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00046722 about?
NCT00046722 is a clinical study titled "Marijuana for HIV-Related Peripheral Neuropathy". To evaluate whether smoked marijuana reduces pain in people with HIV-related peripheral neuropathy.
What is the current status of trial NCT00046722?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2003-01. Estimated completion is 2005-04.
What conditions does trial NCT00046722 study?
This clinical trial studies the following conditions: HIV Infections, Peripheral Nervous System Diseases.
What interventions are being tested in trial NCT00046722?
The interventions under investigation include: Smoked Marijuana (DRUG).
Who is sponsoring clinical trial NCT00046722?
This trial is sponsored by Center for Medicinal Cannabis Research, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00046722 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.